FDA approves Eisai’s epilepsy drug for partial-onset seizures

The Food and Drug Administration on Wednesday approved Eisai’s epilepsy drug Fyompa as a primary treatment for partial-onset seizures in epileptic patients 12 years or older.

Advertisement
By: Mackenzie Bean

Here are three things to know.

  1. Fycompa is a once-daily tablet patients take before bed.
  1. The agency first approved Fyompa in 2012 as an adjunct therapy for partial-onset seizures. The drug can now be used as a sole treatment for the condition.
  1. The drug acts as an agonist to limit the overstimulation of neurons associated with seizures.

More articles on supply chain:

6 must-reads for supply chain leaders this week
Tip: Time back through supply chain workflow optimization
Intermountain adopts needle-free technology for blood draws

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.